Clinical TrialJun 8, 2026, 08:02 AM
Teva's AUSTEDO shows improved TD symptoms, daily living
AI Summary
Teva Pharmaceuticals announced new data from three studies highlighting the comprehensive symptom improvement from AUSTEDO® and AUSTEDO XR® in tardive dyskinesia (TD) patients. The IMPACT-TD Registry showed reductions in Abnormal Involuntary Movement Scale (AIMS) scores in all participants, associated with improved daily living activities, including for those with mild TD. The 3-year RIM-TD study reinforced the importance of sustained treatment, with over 50% of patients responding by week 15 and additional patients improving with continued therapy. Furthermore, a caregiver education study demonstrated an effective strategy to improve TD diagnosis rates.
Key Highlights
- AUSTEDO/AUSTEDO XR treatment led to reductions in Abnormal Involuntary Movement Scale (AIMS) scores in all IMPACT-TD participants.
- IMPACT-TD Registry data showed improved activities of daily living and psychosocial functioning for mild TD patients.
- RIM-TD study found >50% of patients achieved a clinically meaningful response to AUSTEDO by week 15.
- An additional 23% of RIM-TD patients achieved response after week 15 with continued treatment.
- Caregiver education study showed 53% of care recipients at risk of TD discussed it with a provider within six months.
- Caregiver education study resulted in 34% of at-risk individuals receiving a TD diagnosis within six months.
Price Impact
More from TEVA